← Eichor
Condition: Stage Ivb Prostate Cancer Ajcc V8 Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Stage Ivb Prostate Cancer Ajcc V8

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Phase 2 · 1 location(s) · Mayo Clinic · NCT06200103FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer,
Phase 2 · 6 location(s) · Northwestern University · NCT06244004Imaging of Solid Tumors Using 18F-TRX
Phase 1 · 1 location(s) · Rahul Aggarwal · NCT06942104Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT04734730Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Phase 3 · 338 location(s) · SWOG Cancer Research Network · NCT03678025Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Can
Phase 2 · 13 location(s) · National Cancer Institute (NCI) · NCT05691465Nutrition and Exercise Interventions for Androgen Deprivation Therapy-Induced Obese Frailty in Elderly and Non-Elderly S
NA · 1 location(s) · Roswell Park Cancer Institute · NCT03880422Access to Genetic Testing in Underserved Patients With Cancer
NA · 2 location(s) · University of Southern California · NCT06422455Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME T
NA · 1 location(s) · M.D. Anderson Cancer Center · NCT04693377Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to C
Phase 3 · 174 location(s) · SWOG Cancer Research Network · NCT06470243Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration
Phase 1 · 1 location(s) · Roswell Park Cancer Institute · NCT06305598Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Can
Phase 1 · 1 location(s) · Jonsson Comprehensive Cancer Center · NCT05398302177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT07219147Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Pro
Phase 2 · 3 location(s) · University of Washington · NCT06526299Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
Phase 2 · 1 location(s) · Jonsson Comprehensive Cancer Center · NCT06288113Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT06145633Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT06236139PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resist
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT05805371Addressing Health Literacy With a Tailored Survivorship Care Plan
NA · 3 location(s) · Emory University · NCT06674863Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
Phase 2 · 107 location(s) · Alliance for Clinical Trials in Oncology · NCT06632977Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Adva
Phase 3 · 102 location(s) · Alliance for Clinical Trials in Oncology · NCT07200830Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastati
Phase 3 · 195 location(s) · Alliance for Clinical Trials in Oncology · NCT06931340Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Phase 1/Phase 2 · 3 location(s) · University of Michigan Rogel Cancer Center · NCT06616155Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabo
Phase 2 · 582 location(s) · National Cancer Institute (NCI) · NCT03866382Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Phase 3 · 342 location(s) · ECOG-ACRIN Cancer Research Group · NCT04423211Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate C
Phase N/A · 4 location(s) · University of Washington · NCT04489719Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modificatio
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05054296Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Phase 2 · 1 location(s) · University of Utah · NCT05168618Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA St
Phase 2 · 1 location(s) · University of Washington · NCT06039371Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Phase 1/Phase 2 · 1 location(s) · Vadim S Koshkin · NCT05113537
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.